Effects of high- versus standard-dose olmesartan medoxomil on plasma levels of inflammatory markers and aldosterone in patients with essential hypertension

Trial Profile

Effects of high- versus standard-dose olmesartan medoxomil on plasma levels of inflammatory markers and aldosterone in patients with essential hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2012

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Essential hypertension
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 13 May 2012 New trial record
    • 29 Apr 2012 Results presented at the 22nd European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top